Bring Specialized Renal Expertise to Your Preclinical Drug Development
NEPHRIX Biosolutions partners with pharmaceutical and biotech sponsors to de-risk kidney-targeted drug programs from early proof of concept to IND-enabling data.
Why NEPHRIX Biosolutions ?
Deep, Focused Renal Expertise
NEPHRIX Biosolutions expertise is built on the kidney, one of the most demanding organs to model. Every protocol is designed by scientists who understand fibrosis, inflammation, and injury at the cellular and tissue level. This depth of expertise lets sponsors evaluate a molecule’s potential with confidence, and reduce the risk of costly failures at late stages of development.
Nephrology-first models
Every model/assay is validated specifically for kidney physiology
Reference-drug validation
All experimental observations are benchmarked against reference compounds, so sponsors can interpret efficacy signals with confidence.
Full translational pipeline
From mechanistic in vitro assays to in vivo efficacy studies, NEPHRIX Biosolutions covers the path from target validation to proof-of-concept
What We Bring ?
Capabilities Designed to De-Risk Your Renal Program
In vitro assays
Human and rodent renal cell-based assays, including our proprietary DuoXProx™ co-culture platform, with CX7 CellInsight-based high-content imaging.
In vivo models
Validated renal disease models (IRI, UUO, cisplatin AKI, adenine diet, STZ, IgA nephropathy…) covering AKI, CKD, DKD, fibrosis, and glomerulopathy.
Biomarkers & Histology
Renal-specific biomarker panels and histopathology services to quantify fibrosis, injury, and functional readouts across your study.
Milestone-Driven Partnership
Dedicated animal facility and cellular/molecular platforms let us respond quickly from a rapid go/no-go read to a full IND-enabling package.
How we work?
A Transparent, Milestone-Based Process
Step 1- Project discussion
We define your scientific objectives and design a study plan aligned with your milestones.
Step 2 – Laboratory tests
Your molecule is evaluated on the most relevant models, with reference-drug controls.
Step 3 – Data sharing
We review preliminary data together and discuss go/no-go decisions.
Step 4 – Final report
A complete data package with interpretation and development recommendations.
Ready to De-Risk Your Renal Drug Program? Contact us
Talk to our team about your molecule and development timeline. We’ll propose a study plan built around your objectives.